Interpace Diagnostics Group (IDXG)
OTHER OTC:IDXG
Want to see IDXG full AI Analyst Report?
IDXG Stock Chart & Stats
$0.94
$0.00(0.00%)
At close: 4:00 PM EST
$0.94
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.70 - $2.40
Previous CloseN/A
Volume34.00
Average Volume (3M)11.58K
Market Cap
$49.58M
Enterprise Value$45.52M
Total Cash (Recent Filing)$2.65M
Total Debt (Recent Filing)$1.08M
Price to Earnings (P/E)1.6
Beta1.35
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.23
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.01
Enterprise Value/Ebitda11.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Positive Free Cash FlowConsistent positive operating and free cash flow across 2023–2025 and TTM 2026 supports internal funding for operations, limits reliance on external financing, and signals improved earnings quality. Sustained cash generation provides durable flexibility for reinvestment and downturn absorption.
Improved Profitability And Strong Gross MarginsReturn to net profitability with high gross margins (about 59–64%) and positive operating earnings in 2025 and TTM 2026 indicates structural margin strength. This enhances long-term cash conversion, supports pricing power or cost efficiency, and cushions the business against revenue cyclicality.
Lower Leverage And Improved Balance-sheet FlexibilityMaterial debt reduction and a modest debt-to-equity position in 2025 and TTM 2026 lower financial risk and increase strategic optionality. Improved leverage enhances ability to fund operations, invest in growth, or pursue M&A without immediate refinancing strain, strengthening long-term resilience.
Bears Say
Inconsistent Revenue TrendsTop-line volatility—declines in 2025 and again in the TTM 2026 period after a strong 2024—undermines confidence in durable demand growth. Inconsistent revenue makes capacity planning, R&D prioritization, and margin sustainability harder to predict, raising execution risk over the medium term.
Prior Negative Equity HistoryA recent recovery from multiple years of negative equity (2021–2024) highlights past capital erosion. That history reduces the margin for error: weaker operating results or a cash flow setback could more easily erode capital again and constrain access to favorable external financing.
Cash-flow Momentum VolatilityAlthough FCF is currently positive, the decline in TTM 2026 after prior growth and earlier negative cash flow years shows volatility in cash generation. This variability raises the risk that funding for capex, commercialization, or strategic initiatives could tighten if margins or volumes weaken.
Interpace Diagnostics Group News
IDXG FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $0.70 and its highest was $2.40 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $49.58M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Aug 12, 2026 which is in 67 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on May 12, 2026. The company reported $0.026 earnings per share for the quarter, beating the consensus estimate of N/A by $0.026.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.026 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -5%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Technical Analysis
―
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
83.99% Insiders
<0.01% Other Institutional Investors
16.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---